The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease

Jason Karlawish of the Perelman School of Medicine spoke about the ramifications of the FDA’s approval of Aduhelm, an Alzheimer’s drug. “One of the consequences is that other companies will say, ‘If this is your new lower bar, we want our drugs approved on that basis,’” he said. “Companies are companies, I can’t fault them for doing what companies do, but we have now unleashed drugs that we are not sure what the benefits are, and that could have enormous consequences.”

・ From The Washington Post